Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease

Paul D. Mintz, Nathan M. Bass, Lawrence D. Petz, Randolph Steadman, Michael B Streiff, Jeffery McCullough, Sandra Burks, David Wages, Sally Van Doren, Laurence Corash

Research output: Contribution to journalArticle

Abstract

An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled, double-blinded, randomized study was conducted to evaluate the efficacy and safety of PCT-FFP compared with conventional FFP (C-FFP). Patients (n = 121) with acquired coagulopathy, largely due to liver disease, including hepatic transplantation, were transfused with either PCT-FFP or C-FFP for up to 7 days. Primary end points were changes in the prothrombin time (PT) and the partial thromboplastin time (PTT) in response to the first FFP transfusion. Secondary analyses compared changes in the PT and the PTT, factor VII levels, clinical hemostasis, blood component usage, and safety following FFP transfusions for up to 7 days. Following the first transfusion, correction in the PT and PTT adjusted for FFP dose and patient weight was not different. Changes in the PT were equivalent between treatment groups (P = .002 by noninferiority). Equivalence was not demonstrated for changes in the PTT. Following multiple transfusions, correction of the PT and the PTT was similar between groups. No differences were observed in use of blood components, clinical hemostasis, or safety. These results suggest PCT-FFP supported hemostasis in the treatment of acquired coagulopathy similarly to conventional FFP.

Original languageEnglish (US)
Pages (from-to)3753-3760
Number of pages8
JournalBlood
Volume107
Issue number9
DOIs
StatePublished - May 1 2006
Externally publishedYes

Fingerprint

Thromboplastin
Prothrombin
Liver
Liver Diseases
Partial Thromboplastin Time
Prothrombin Time
Plasmas
Hemostasis
Blood
Safety
Therapeutics
Factor VII
Photochemical Processes
Pathogens
Liver Transplantation
Weights and Measures

ASJC Scopus subject areas

  • Hematology

Cite this

Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. / Mintz, Paul D.; Bass, Nathan M.; Petz, Lawrence D.; Steadman, Randolph; Streiff, Michael B; McCullough, Jeffery; Burks, Sandra; Wages, David; Van Doren, Sally; Corash, Laurence.

In: Blood, Vol. 107, No. 9, 01.05.2006, p. 3753-3760.

Research output: Contribution to journalArticle

Mintz, PD, Bass, NM, Petz, LD, Steadman, R, Streiff, MB, McCullough, J, Burks, S, Wages, D, Van Doren, S & Corash, L 2006, 'Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease', Blood, vol. 107, no. 9, pp. 3753-3760. https://doi.org/10.1182/blood-2004-03-0930
Mintz, Paul D. ; Bass, Nathan M. ; Petz, Lawrence D. ; Steadman, Randolph ; Streiff, Michael B ; McCullough, Jeffery ; Burks, Sandra ; Wages, David ; Van Doren, Sally ; Corash, Laurence. / Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. In: Blood. 2006 ; Vol. 107, No. 9. pp. 3753-3760.
@article{f0b97d06735344d7a7a85c5ce3a95c91,
title = "Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease",
abstract = "An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled, double-blinded, randomized study was conducted to evaluate the efficacy and safety of PCT-FFP compared with conventional FFP (C-FFP). Patients (n = 121) with acquired coagulopathy, largely due to liver disease, including hepatic transplantation, were transfused with either PCT-FFP or C-FFP for up to 7 days. Primary end points were changes in the prothrombin time (PT) and the partial thromboplastin time (PTT) in response to the first FFP transfusion. Secondary analyses compared changes in the PT and the PTT, factor VII levels, clinical hemostasis, blood component usage, and safety following FFP transfusions for up to 7 days. Following the first transfusion, correction in the PT and PTT adjusted for FFP dose and patient weight was not different. Changes in the PT were equivalent between treatment groups (P = .002 by noninferiority). Equivalence was not demonstrated for changes in the PTT. Following multiple transfusions, correction of the PT and the PTT was similar between groups. No differences were observed in use of blood components, clinical hemostasis, or safety. These results suggest PCT-FFP supported hemostasis in the treatment of acquired coagulopathy similarly to conventional FFP.",
author = "Mintz, {Paul D.} and Bass, {Nathan M.} and Petz, {Lawrence D.} and Randolph Steadman and Streiff, {Michael B} and Jeffery McCullough and Sandra Burks and David Wages and {Van Doren}, Sally and Laurence Corash",
year = "2006",
month = "5",
day = "1",
doi = "10.1182/blood-2004-03-0930",
language = "English (US)",
volume = "107",
pages = "3753--3760",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease

AU - Mintz, Paul D.

AU - Bass, Nathan M.

AU - Petz, Lawrence D.

AU - Steadman, Randolph

AU - Streiff, Michael B

AU - McCullough, Jeffery

AU - Burks, Sandra

AU - Wages, David

AU - Van Doren, Sally

AU - Corash, Laurence

PY - 2006/5/1

Y1 - 2006/5/1

N2 - An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled, double-blinded, randomized study was conducted to evaluate the efficacy and safety of PCT-FFP compared with conventional FFP (C-FFP). Patients (n = 121) with acquired coagulopathy, largely due to liver disease, including hepatic transplantation, were transfused with either PCT-FFP or C-FFP for up to 7 days. Primary end points were changes in the prothrombin time (PT) and the partial thromboplastin time (PTT) in response to the first FFP transfusion. Secondary analyses compared changes in the PT and the PTT, factor VII levels, clinical hemostasis, blood component usage, and safety following FFP transfusions for up to 7 days. Following the first transfusion, correction in the PT and PTT adjusted for FFP dose and patient weight was not different. Changes in the PT were equivalent between treatment groups (P = .002 by noninferiority). Equivalence was not demonstrated for changes in the PTT. Following multiple transfusions, correction of the PT and the PTT was similar between groups. No differences were observed in use of blood components, clinical hemostasis, or safety. These results suggest PCT-FFP supported hemostasis in the treatment of acquired coagulopathy similarly to conventional FFP.

AB - An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled, double-blinded, randomized study was conducted to evaluate the efficacy and safety of PCT-FFP compared with conventional FFP (C-FFP). Patients (n = 121) with acquired coagulopathy, largely due to liver disease, including hepatic transplantation, were transfused with either PCT-FFP or C-FFP for up to 7 days. Primary end points were changes in the prothrombin time (PT) and the partial thromboplastin time (PTT) in response to the first FFP transfusion. Secondary analyses compared changes in the PT and the PTT, factor VII levels, clinical hemostasis, blood component usage, and safety following FFP transfusions for up to 7 days. Following the first transfusion, correction in the PT and PTT adjusted for FFP dose and patient weight was not different. Changes in the PT were equivalent between treatment groups (P = .002 by noninferiority). Equivalence was not demonstrated for changes in the PTT. Following multiple transfusions, correction of the PT and the PTT was similar between groups. No differences were observed in use of blood components, clinical hemostasis, or safety. These results suggest PCT-FFP supported hemostasis in the treatment of acquired coagulopathy similarly to conventional FFP.

UR - http://www.scopus.com/inward/record.url?scp=33646387404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646387404&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-03-0930

DO - 10.1182/blood-2004-03-0930

M3 - Article

C2 - 16410447

AN - SCOPUS:33646387404

VL - 107

SP - 3753

EP - 3760

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -